Calcitonin Gene-related Peptide Levels in Chronic Migraine

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Chronic Migraine
Interventions
DRUG

OnabotulinumtoxinA

"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."

DRUG

Saline

"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."

Trial Locations (2)

11803

Island Neurological Associates, P.C., Plainview

65807

Clinvest, Springfield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Cady, Roger, M.D.

INDIV

NCT01071096 - Calcitonin Gene-related Peptide Levels in Chronic Migraine | Biotech Hunter | Biotech Hunter